Syndax Pharmaceuticals Inc’s recent filing unveils that its Chief Executive Officer Metzger Michael A unloaded Company’s shares for reported $2.58 million on Sep 08 ’25. In the deal valued at $16.41 per share,157,307 shares were sold. As a result of this transaction, Metzger Michael A now holds 298,661 shares worth roughly $4.91 million.
Then, MICHAEL METZGER bought 157,307 shares, generating $2,680,511 in total proceeds.
Before that, Podlesak Dennis sold 19,200 shares. Syndax Pharmaceuticals Inc shares valued at $304,170 were divested by the Director at a price of $15.84 per share. As a result of the transaction, Podlesak Dennis now holds 191,763 shares, worth roughly $3.15 million.
BTIG Research also remained covering SNDX and reiterated its “Buy” recommendation on August 05, 2025. Goldman started covering the stock on July 10, 2025. It rated SNDX as “a Buy”.
Price Performance Review of SNDX
On Tuesday, Syndax Pharmaceuticals Inc [NASDAQ:SNDX] saw its stock jump 0.30% to $16.45. Over the last five days, the stock has gained 6.92%. Syndax Pharmaceuticals Inc shares have fallen nearly -11.99% since the year began. Nevertheless, the stocks have risen 24.43% over the past one year. While a 52-week high of $22.50 was reached on 08/28/25, a 52-week low of $8.58 was recorded on 05/15/25.
Levels Of Support And Resistance For SNDX Stock
The 24-hour chart illustrates a support level at 16.24, which if violated will result in even more drops to 16.03. On the upside, there is a resistance level at 16.73. A further resistance level may holdings at 17.01.
How much short interest is there in Syndax Pharmaceuticals Inc?
A steep rise in short interest was recorded in Syndax Pharmaceuticals Inc stocks on 2025-09-15, growing by 2.54 million shares to a total of 23.14 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-15 was 20.61 million shares. There was a rise of 10.96%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 24, 2024 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $37 price target.
